News | March 26, 2015

Edwards' CEO Addresses Senate Committee on Preserving, Strengthening U.S. Medical Device Innovation

Comments highlight improved collaboration, need to reduce regulatory and financial barriers

March 26, 2015 — Edwards Lifesciences Corp. announced that chairman and CEO Michael A. Mussallem served as an invited expert panelist on behalf of the Advanced Medical Technology Association (AdvaMed) at the United States Senate Health, Education, Labor and Pensions Committee hearing on "Continuing America's Leadership: Advancing Research and Development for Patients."

"As medical technology innovators, it's our passion and mission to continue developing better solutions to improve the lives of patients," said Mussallem.  "To maximize the impact of this work, it is imperative that we forge a path toward revitalizing the medical technology ecosystem in the United States. Continued innovation is vital to improving clinical outcomes, enhancing patients' quality of life and bringing increased value to the healthcare system."

Mussallem noted collaborative engagement and significant progress by the U.S. Food & Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) in better understanding and improving the predictability and approval timelines for future generations of medical devices.

He also addressed opportunities to further reduce barriers in regulatory approval and reimbursement, in order to help promote America's continued worldwide leadership in medical device development and also to support innovation. His comments focused on three primary areas:

  • the acceleration of FDA's vision to improve the regulatory process;
  • the need to strengthen the research and development infrastructure so it is second to none; and
  • continued encouragement of innovation by addressing issues throughout the entire ecosystem.


Mussallem also drew upon Edwards' experience with the Sapien transcatheter aortic heart valves to discuss the current regulatory environment in the United States.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Overlay Init